CLONE SCAN (A)

What is Clone Scan (G) test?

Clone Scan (G) is a longitudinal, allele-specific MRD assay that tracks the patient’s baseline clonotype(s) identified by Clone Detect using UMI barcoding and deep sequencing.

Designed for ongoing monitoring after therapy milestones to quantify MRD with ultra-high sensitivity

Why consider Clone Scan (G) test?

• Provides precise MRD quantification to assess depth and durability of response, enabling earlier intervention at molecular recurrence.
• Facilitates standardized MRD timepoints across clinical pathways (post‑induction, post‑transplant, maintenance) with consistent methodology.

Who should get this Clone Scan (G) test?

• Patients already profiled by Clone Detect who require serial MRD assessments throughout treatment and follow‑
• Particularly valuable in multiple myeloma, B‑ALL, and mantle cell lymphoma where MRD status guides prognosis and therapeutic choices.

More Information about Clone Scan (G) test

Minimal residual disease (MRD) is the very small number of cancer cells that remain after treatment and are below the detection limits of standard tests, and its presence or absence is a powerful predictor of outcome in multiple myeloma. Modern assays such as next‑generation flow cytometry and next‑generation sequencing measure MRD in bone marrow with sensitivities, with sustained MRD negativity associated with longer progression‑free and overall survival across disease settings. 

OTHER NAMES: Longitudinal MRD assay, MRD clonotype identification, ClonoSeq, MRD monitoring